全文获取类型
收费全文 | 5315篇 |
免费 | 313篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 89篇 |
儿科学 | 226篇 |
妇产科学 | 94篇 |
基础医学 | 499篇 |
口腔科学 | 122篇 |
临床医学 | 346篇 |
内科学 | 1051篇 |
皮肤病学 | 154篇 |
神经病学 | 310篇 |
特种医学 | 193篇 |
外科学 | 1191篇 |
综合类 | 165篇 |
预防医学 | 242篇 |
眼科学 | 210篇 |
药学 | 264篇 |
中国医学 | 32篇 |
肿瘤学 | 454篇 |
出版年
2023年 | 53篇 |
2022年 | 101篇 |
2021年 | 214篇 |
2020年 | 101篇 |
2019年 | 122篇 |
2018年 | 155篇 |
2017年 | 110篇 |
2016年 | 150篇 |
2015年 | 121篇 |
2014年 | 180篇 |
2013年 | 262篇 |
2012年 | 389篇 |
2011年 | 344篇 |
2010年 | 239篇 |
2009年 | 151篇 |
2008年 | 273篇 |
2007年 | 299篇 |
2006年 | 274篇 |
2005年 | 275篇 |
2004年 | 261篇 |
2003年 | 204篇 |
2002年 | 161篇 |
2001年 | 143篇 |
2000年 | 110篇 |
1999年 | 85篇 |
1998年 | 53篇 |
1997年 | 47篇 |
1996年 | 43篇 |
1995年 | 38篇 |
1994年 | 26篇 |
1993年 | 17篇 |
1992年 | 60篇 |
1991年 | 58篇 |
1990年 | 40篇 |
1989年 | 55篇 |
1988年 | 47篇 |
1987年 | 31篇 |
1986年 | 27篇 |
1985年 | 44篇 |
1984年 | 38篇 |
1983年 | 28篇 |
1982年 | 18篇 |
1981年 | 12篇 |
1980年 | 23篇 |
1979年 | 22篇 |
1978年 | 15篇 |
1976年 | 13篇 |
1974年 | 21篇 |
1973年 | 12篇 |
1972年 | 12篇 |
排序方式: 共有5642条查询结果,搜索用时 0 毫秒
81.
Ankit Batra Jayachandran Perumal Kalaiyarasi Krishnarathinam Kannan Nikita Mehra Prasanth Ganesan Parathan Karunakaran Manikandan Dhanushkodi Gangothri Selvarajan Arun Kumar Rajan Sivasree Kesana Trivadi Ganesan Tenali G. Sagar Venkatraman Radhakrishnan 《Indian journal of hematology & blood transfusion》2021,37(3):463
There has been a surge in haploidentical hematopoietic stem cell transplantation (HSCT) in India recently. However, there is a paucity of data on haploidentical HSCT from India. The report is an analysis of data of haploidentical HSCT performed at our center. Analysis of patients with acute leukemia or chronic myeloid leukemia who underwent haploidentical HSCT during 2014–2019 was performed. The graft versus host disease (GVHD) prophylaxis was post-transplant Cyclophosphamide with Mycophenolate-mofetil and Cyclosporine. All patients were transfused peripheral blood stem cells from donors. Overall survival (OS) was calculated using the Kaplan–Meier method. Twenty-one patients underwent haploidentical HSCT. Fourteen-patients were males. The median age of patients was 15 years. Fludarabine with total body irradiation was the most common conditioning regimen (n = 15, 71.4%). The median duration for neutrophil and platelet engraftment was 14 days. Cumulative incidence of acute and chronic GVHD was 19%, and 38% respectively. The median follow-up was 26 months and the two-year OS was 38%. Twelve (57%) patients died during the study period, 8 patients (38%) died from transplant-related mortality (TRM), and 4 from disease relapse. Sepsis was the cause of death in six of the eight TRM. Nine out of 21 patients (42.8%) are leukemia-free on follow-up. Haploidentical HSCT is a promising modality of treatment in patients who have no suitable matched donors. Though the TRM remains high, good disease control was achieved in 42.8% of patients. Multi-drug resistant bacterial infection remains a challenge in performing haploidentical HSCT in developing countries. 相似文献
82.
Quraishi ER Goel S Gupta M Catanzaro A Zasuwa G Divine G 《The American journal of gastroenterology》2005,100(10):2288-2293
OBJECTIVES: The primary aim of this study is to determine if patients with end-stage renal disease (ESRD) on peritoneal dialysis (PD) have a higher risk of developing acute pancreatitis (AP) than patients on hemodialysis (HD). The secondary aim is to compare the outcomes of AP between the two groups. METHOD: This is a retrospective case-control study. The study groups consisted of all patients initiated on HD and PD between January 1, 1998 and August 1, 2003. AP was identified using ICD-9 codes. Statistical analysis was carried out using Poisson regression, Kaplan-Meier curve, log-rank test, and Cox regression. RESULTS: One thousand two hundred and thirty-three and 160 eligible patients were identified in the HD and PD groups, respectively. Twenty-eight patients had AP. Eight patients were excluded as they had identifiable etiologies for AP. Of the remaining 20 patients with AP, 14 were in the HD group and 6 were in the PD group (p= 0.009). Incidence of AP was 18.4 per 1,000 person-years in the PD group and 6.5 per 1,000 person-years in the HD group (p= 0.033). Kaplan-Meier curves showed a significant difference in AP-free survival between the two groups (log-rank p= 0.026). Using time-dependent analysis, the hazard ratio for AP in PD patients after adjustment for age and sex was 3.94 (p= 0.006). There was no observed difference in length of hospital stay and ICU stay. All cases of AP were interstitial. There were no complications or deaths related to AP. CONCLUSION: PD is a risk factor for AP. There is no statistical difference in AP-related mortality and morbidity between HD and PD. 相似文献
83.
Vitamin E-based therapy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease. 总被引:3,自引:0,他引:3
Kaushal Madan Yogesh Batra Datta S Gupta Bal Chander K D Anand Rajan Rajvir Singh S K Panda S K Acharya 《Indian journal of gastroenterology》2005,24(6):251-255
BACKGROUND: Comparative trials of ursodeoxycholic acid (UDCA), vitamin E and weight management programs among patients with nonalcoholic fatty liver disease (NAFLD) are lacking. AIM: To find an effective single agent or combination of agents for management of NAFLD. METHODS: In this retrospective study, consecutive patient with histologically confirmed NAFLD with raised ALT were included. The patients received either weight management (exercise and therapeutic lifestyle changes [TLC] diet with a target to reduce body weight 10% in 6 months) (group I) ; weight management + UDCA (300 mg BID) (group II); or weight management + UDCA + vitamin E (400 mg OD) (group III). Outcome measure was normalization of ALT. RESULTS: 42 patients (18, 12 and 12 in groups I, II and III, respectively) were included between 1996 and 2004. All patients in group III normalized their ALT levels, which was significantly higher than numbers in group I (8/18) and group II (5/12); (p=0.003). Post treatment ALT was significantly lower in group III (28.6 [9.3]) as compared to group I (59.3 [32.2]) and group II (49.0[31.8]); (p=0.01). Type of therapy received was the only factor predictive of ALT normalization. CONCLUSION: Combination regimen containing vitamin E appears to be effective in normalizing ALT among NAFLD patients. 相似文献
84.
Piyush Gupta Mehul Choksi Ashish Goel Uday Zachariah Kattiparambil Gangadharan Sajith Jeyamani Ramachandran George Chandy George Kurian Grace Rebekah Chundamannil Eapen Eapen 《Indian journal of gastroenterology》2018,37(1):31-38
Background
Experience with zinc in treating symptomatic hepatic Wilson’s disease (WD) is limited.Aim
To study the efficacy of Penicillamine followed by zinc in treating symptomatic hepatic Wilson’s disease.Methods
We retrospectively analyzed case records of 31 symptomatic hepatic WD patients for whom disease severity scores (Child’s, model for end-stage liver disease (MELD), Nazer’s, and New Wilson Index (NWI) score) and 24-h urinary copper were compared at 3-time points—baseline at presentation, at transition from penicillamine to zinc and at end of follow up.Results
Thirty-one patients (median age 11 [5–24] years) with symptomatic hepatic WD were studied; ten had associated neuropsychiatric manifestations of WD. Penicillamine was changed to zinc sulfate either due to financial constraints (28 patients) or due to adverse effects of penicillamine (3 patients). At presentation (baseline), six patients belonged to Child’s class A, five to Child’s B, and 17 to Child’s C. Duration of initial penicillamine chelation therapy was 134 (2–320) weeks, and of subsequent zinc therapy was 363 (35–728) weeks. There was a significant improvement in liver function tests and disease severity scores (Child’s, MELD, Nazer’s, and NWI score) at the transition from penicillamine to zinc compared to baseline. This improvement was maintained until the end of study period with 90% survival at 10 (2–20) years. Fifteen of the 17 Child’s C cirrhotic patients showed significant improvement in disease severity scores from baseline until end of follow up.Conclusions
Penicillamine followed by zinc may be a safe and effective treatment in resource-constrained setting for symptomatic hepatic WD patients in all grades of baseline disease severity. Some patients with decompensated cirrhosis due to WD may be managed with medical treatment, avoiding liver transplantation.85.
Pravin K Goel 《Catheterization and cardiovascular interventions》2005,66(2):281-285
This report describes a simple angiographic viewing rule for coronary angiography in patients of dextrocardia with obstructive coronary artery disease, which could correct the unfamiliar angulated pictures of the coronary tree in dextrocardia into the familiar conventional angiographic pictures of a normally located heart and its associated ease of interpretation. 相似文献
86.
The novel 1,3,4,11b‐tetrahydro‐1H‐fluoreno[9,1‐cd]azepine framework, a structurally rigidified variant of the 1‐phenylbenzazepine template, was synthesized via direct arylation as a key reaction. Evaluation of the binding affinities of the rigidified compounds across a battery of serotonin, dopamine, and adrenergic receptors indicates that this scaffold unexpectedly has minimal affinity for D1 and other dopamine receptors and is selective for the 5‐HT6 receptor. The affinity of these systems at the 5‐HT6 receptor is significantly influenced by electronic and hydrophobic interactions as well as the enhanced rigidity of the ligands. Molecular docking studies indicate that the reduced D1 receptor affinity of the rigidified compounds may be due in part to weaker H‐bonding interactions between the oxygenated moieties on the compounds and specific receptor residues. Key receptor–ligand H‐bonding interactions, salt bridges, and π–π interactions appear to be responsible for the 5‐HT6 receptor affinity of the compounds. Compounds 10 (6,7‐dimethoxy‐2,3,4,11b‐tetrahydro‐1H‐fluoreno[9,1‐cd]azepine) and 12 (6,7‐dimethoxy‐2‐methyl‐2,3,4,11b‐tetrahydro‐1H‐fluoreno[9,1‐cd]azepine) have been identified as structurally novel, high affinity (Ki = 5 nM), selective 5‐HT6 receptor ligands. 相似文献
87.
88.
Leon Kao Jessica Rajan Lonnie Roy Eric Kavosh David A. Khan 《Annals of allergy, asthma & immunology》2013,110(2):86-91.e1
BackgroundDrug challenge is a useful tool when diagnostic testing lacks predictive value for a questionable history of drug allergy. Placebo-controlled drug challenge studies demonstrate that a significant number of patients report purely subjective symptoms to placebo.ObjectiveTo evaluate the safety and rate of adverse effects when performing drug challenges and to identify predictive factors for occurrences of subjective symptoms during drug challenges.MethodsWe performed a 6-year, retrospective medical record review of patients who underwent drug challenges by members of the Allergy and Immunology Division after consultation deemed drug challenges to be appropriate. Statistical analysis was performed to compare the proportion of patients with subjective symptoms based on certain factors, including sex, age, number of listed drug allergies, interval from historical drug reaction to the drug challenge, and types of historical reaction.ResultsA total of 114 patients underwent 123 drug challenges. Only 1 patient was deemed to have a true positive drug challenge result. Twenty patients reported subjective symptoms during graded challenge, all of which were not deemed a positive challenge. There was a significantly higher proportion of patients who reported subjective symptoms in females, those with a higher number of listed drug allergies, and those whose historical reactions were primarily subjective in nature.ConclusionDrug challenges are safe procedures in appropriately selected patients. A number of patients report subjective symptoms during drug challenges. Identifying patients at high risk for subjective symptoms may assist in determining whether placebo-controlled drug challenges should be performed. 相似文献
89.
90.